Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSC in Intermittent Claudication
NCT00725881Phase 2Completed
- Sponsor
- Diffusion Pharmaceuticals Inc.
- Start
- Aug 2008
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of trans sodium crocetinate in intermittent claudication (IC) (9 arms), sponsored by Diffusion Pharmaceuticals Inc. Primary endpoints: Safety assessments and Pharmacokinetic assessments. Started Aug 2008; status: completed.
02
Drugs
trans sodium crocetinate
03
Conditions
intermittent claudication (IC)
Beyond the preview
Go deeper on NCT00725881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00725881.